The underlying molecular mechanisms leading to anti-VE-cadherin autoantibodies production need to be clarified, comparing anti-VE-cadherin autoantibodies in patients with RA and vasculitis versus patients with RA without vasculitis. This evidence concerns the gene CDH5 and rheumatoid arthritis.